ArticleAbdominal radiology (New York)2026
Artificial intelligence-driven CT radiomics model predicts prognosis in TACE-refractory hepatocellular carcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Human-AI Interaction in Interventional Radiology: A Narrative Review of Current Applications, Challenges, and Future Directions.Journal of imaging · 2026Review
- Artificial intelligence in transarterial chemoembolization for hepatocellular carcinoma: from treatment response prediction to refractoriness assessment.Frontiers in oncology · 2026Review
- Multi-omics and spatial transcriptomics decode the ZDHHC9-driven hypoxia-immunosuppressive axis in hepatocellular carcinoma.Frontiers in oncology · 2026Article
- Preoperative Prediction of TACE Refractoriness in Hepatocellular Carcinoma Using CT-Based Radiomics Model.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo develop an integrated predictive model combining radiomics, clinical risk factors, and machine learning for prognostic assessment in hepatocellular carcinoma (HCC) patients receiving continued transarterial chemoembolization (TACE) after developing TACE resistance. MATERIALS AND
methodsIn this retrospective study, 108 HCC patients with TACE resistance treated between September 2015 and September 2024 were analyzed. The dataset was randomly divided into training (70%) and test (30%) cohorts. Radiomics features were extracted from both intratumoral and peritumoral regions, with margins of 3 mm, 6 mm, and 10 mm. Subsequently, radiomics scores (rad-scores) were computed. Multiple machine learning algorithms were evaluated for model performance.
resultsMultivariate analysis identified Barcelona Clinic Liver Cancer (BCLC) stage and lymphocyte-to-monocyte ratio (LMR) as independent prognostic factors. The support vector machine (SVM)-based combined model showed the highest predictive accuracy, with an area under the curve (AUC) of 0.956 (95% CI: [0.910-1.000]) in the training cohort and 0.897 (95% CI: [0.772-1.000]) in the test cohort, significantly surpassing models using only clinical or radiomics data. Survival analysis revealed a longer median survival in the low rad-score group (< 3.05) compared to the high rad-score group (33 vs. 22 months; p = 0.009) and in the high-LMR group versus the low-LMR group (32 vs. 15 months; p < 0.001).
conclusionThe machine learning-based combined model can effectively predict the prognosis of HCC patients who continue TACE after developing TACE resistance. Rad-score, BCLC stage, and LMR are potential prognostic indicators for repeated TACE following TACE refractoriness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.